CN111838659A - Substance for regulating body satiety hormone and application thereof - Google Patents
Substance for regulating body satiety hormone and application thereof Download PDFInfo
- Publication number
- CN111838659A CN111838659A CN202010720978.0A CN202010720978A CN111838659A CN 111838659 A CN111838659 A CN 111838659A CN 202010720978 A CN202010720978 A CN 202010720978A CN 111838659 A CN111838659 A CN 111838659A
- Authority
- CN
- China
- Prior art keywords
- parts
- substance
- hormone
- satiety
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036186 satiety Effects 0.000 title claims abstract description 53
- 235000019627 satiety Nutrition 0.000 title claims abstract description 53
- 229940088597 hormone Drugs 0.000 title claims abstract description 51
- 239000005556 hormone Substances 0.000 title claims abstract description 51
- 239000000126 substance Substances 0.000 title claims abstract description 40
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 24
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims abstract description 38
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 claims abstract description 38
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 claims abstract description 38
- NCDCLPBOMHPFCV-UHFFFAOYSA-N hexyl hexanoate Chemical compound CCCCCCOC(=O)CCCCC NCDCLPBOMHPFCV-UHFFFAOYSA-N 0.000 claims abstract description 38
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 claims abstract description 19
- 229940067592 ethyl palmitate Drugs 0.000 claims abstract description 19
- FGPPDYNPZTUNIU-UHFFFAOYSA-N pentyl pentanoate Chemical compound CCCCCOC(=O)CCCC FGPPDYNPZTUNIU-UHFFFAOYSA-N 0.000 claims abstract description 19
- OALYTRUKMRCXNH-UHFFFAOYSA-N 5-pentyloxolan-2-one Chemical compound CCCCCC1CCC(=O)O1 OALYTRUKMRCXNH-UHFFFAOYSA-N 0.000 claims abstract description 15
- 230000001276 controlling effect Effects 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 20
- 235000019789 appetite Nutrition 0.000 claims description 8
- 230000036528 appetite Effects 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 235000003642 hunger Nutrition 0.000 abstract description 20
- 235000013305 food Nutrition 0.000 abstract description 6
- 235000012054 meals Nutrition 0.000 abstract description 4
- 235000019577 caloric intake Nutrition 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 44
- 241000700159 Rattus Species 0.000 description 31
- 230000003247 decreasing effect Effects 0.000 description 24
- 102000004877 Insulin Human genes 0.000 description 22
- 108090001061 Insulin Proteins 0.000 description 22
- 229940125396 insulin Drugs 0.000 description 22
- 102100025841 Cholecystokinin Human genes 0.000 description 21
- 101800001982 Cholecystokinin Proteins 0.000 description 21
- 101800001586 Ghrelin Proteins 0.000 description 21
- 102400000442 Ghrelin-28 Human genes 0.000 description 21
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 21
- 229940107137 cholecystokinin Drugs 0.000 description 21
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 21
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 21
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 19
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 19
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 19
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 8
- 102100029909 Peptide YY Human genes 0.000 description 8
- 108010088847 Peptide YY Proteins 0.000 description 8
- 210000000702 aorta abdominal Anatomy 0.000 description 8
- 230000003054 hormonal effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- -1 PYY Chemical compound 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a substance for regulating and controlling body satiety hormone and application thereof. The material comprises the following components in parts by weight: 6-25 parts of coconut aldehyde, 10-39 parts of amyl valerate, 13-22 parts of nerol, 2-42 parts of hexyl hexanoate, 8-28 parts of ethyl palmitate and 1-18 parts of ethyl stearate. The substance capable of improving the satiety hormone of the body and reducing the hunger hormone of the body is utilized by the body in a sniffing mode, is convenient to apply, has wide application scenes and prospects, and overcomes the problem of extra energy intake in the absorption of the traditional weight-reducing food or meal replacement because the substance is zero energy per se.
Description
Technical Field
The invention relates to a substance for regulating and controlling body satiety hormone and application thereof.
Background
Along with the arrival of the times of excess nutrition, the number of obese people increases year by year, and the 2016 Lancet statistics shows that the number of overweight people reaches more than 3 hundred million in China, 8960 ten thousand of obese people, and overweight or obese people face the trouble of a plurality of chronic diseases. In China, the proportion of diabetes, cardiovascular diseases, obesity, hyperlipidemia, hypertension and the like is continuously increased, and the incidence rate is 4-6 times that of developed countries such as the United states. Therefore, effective weight reduction is a technological problem to be overcome at present. At present, a plurality of weight-losing products or meal-replacing foods are available on the market, but the weight-losing products or meal-replacing foods are chewed and eaten, and more or less additional energy is added to the body, so that the weight-losing effect is poor.
Six hormones involved in satiety in the body are InsuLin (InsuLin), ghrelin (ghrelin), glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) and YY Peptide (PYY), respectively.
Insulin is a protein hormone secreted by islet beta cells in the pancreas stimulated by endogenous or exogenous substances such as glucose, lactose, ribose, arginine, glucagon, etc., and is the only hormone in the body that reduces blood sugar. When insulin is secreted in a large amount, blood sugar is rapidly reduced, the body can feel hunger, and the strength of satiety of the body can be reflected from the side.
As a unique peripheral hormone, ghrelin promotes appetite and increases food intake, and the amount of ghrelin in blood reflects the strength of satiety from the side.
The glucose-dependent insulinotropic hormone secretion polypeptide is a gastrointestinal tract hormone synthesized and secreted by the upper segments of duodenum and jejunum, is a main incretin hormone, has the effects of regulating insulin secretion, promoting maturation and differentiation of fat cells, promoting absorption of nutrient substances and the like, and induces an organism to generate stronger satiety.
Glucagon-like peptide-1, as an incretin hormone, amplifies the response of insulin to glucose uptake and inhibits the release of glycogen in the liver. In the gastrointestinal tract, glucagon-like peptide-1 inhibits gastric and pancreatic secretion and gastric emptying, contributing to enhanced satiety.
The satiety induced by cholecystokinin is regulated by activation of the vagus nerve in the stomach and duodenum, and cholecystokinin also slows gastric emptying and keeps the stomach distended, resulting in greater satiety.
YY peptide suppresses appetite by activating the homeostatic center of the hypothalamus to suppress its expression of neuropeptide Y. The YY peptide can activate the ileum brake effect, delay gastric emptying and nutrient absorption and is beneficial to enhancing the satiety of the organism.
How to regulate the hormone related to the satiety of the body so as to enhance the satiety of the body, reduce the appetite and avoid the intake of extra energy as much as possible has good application prospect in solving the problem of obese and overweight people.
Disclosure of Invention
The invention aims to provide a substance for regulating body satiety hormone, which can regulate body and satiety related hormone so as to reduce body appetite, and simultaneously does not need to be chewed and eaten like traditional weight-reducing products or meal replacement foods, thereby adding extra energy to the body and ensuring that the weight-reducing effect is poor.
The technical scheme adopted by the invention is as follows:
a substance for regulating and controlling body satiety hormone comprises the following components in parts by weight: 6-25 parts of coconut aldehyde, 10-39 parts of amyl valerate, 13-22 parts of nerol, 2-42 parts of hexyl hexanoate, 8-28 parts of ethyl palmitate and 1-18 parts of ethyl stearate.
Preferably, the components are composed of the following components in parts by weight: 25 parts of coconut aldehyde, 15 parts of amyl valerate, 20 parts of nerol, 15 parts of hexyl hexanoate, 10 parts of ethyl palmitate and 15 parts of ethyl stearate.
Or the components in parts by weight are as follows: 20 parts of coconut aldehyde, 18 parts of amyl valerate, 18 parts of nerol, 20 parts of hexyl hexanoate, 15 parts of ethyl palmitate and 9 parts of ethyl stearate.
Or the components in parts by weight are as follows: 15 parts of coconut aldehyde, 15 parts of amyl valerate, 22 parts of nerol, 15 parts of hexyl hexanoate, 17 parts of ethyl palmitate and 16 parts of ethyl stearate.
Or the components in parts by weight are as follows: 15 parts of coconut aldehyde, 30 parts of amyl valerate, 15 parts of nerol, 10 parts of hexyl hexanoate, 20 parts of ethyl palmitate and 10 parts of ethyl stearate.
The hormone substance capable of regulating and controlling body satiety is well applied to the aspect of reducing the appetite of the body.
Preferably, the substance or the contents containing the substance can be administered to the body by sniffing. Specifically, the odor may be achieved by spraying or volatilizing.
Further, the substance can be dissolved in ethanol, and then smelled, wherein the mass concentration of the components in ethanol is 0.1-12%, and the ethanol is preferably anhydrous ethanol.
The sniffing time is not less than 5S, but preferably from 5S to 200 min.
In particular applications, the substances may be applied in food supplements, health products, pharmaceuticals and in packages that release the substances. As long as the corresponding application is possible in such a way that the body can smell the components as desired. For example: the product can be used as additive or additive component in food, perfume, or bead for perfuming, medicine, and health product, and can be used in package, equipment for dispersing, volatilizing, or spraying.
The energy of the components contained in the substance is basically zero, and the animal body hormone test and the animal daily ration test show that the body smells the components compounded in the invention, so that the regulation and control of the hormone related to the body satiety can be well realized, the hunger sensation can be further reduced, the satiety can be enhanced, the food intake of three meals can be further reduced, the energy intake of the body can be reduced, and the weight-reducing effect can be achieved.
Compared with the prior art, the invention has the following advantages:
the invention provides a substance capable of regulating and controlling satiety of an organism, which is utilized by the organism in a sniffing mode, is convenient to apply, has wide application scenes and prospects, and overcomes the problem of extra energy intake when the traditional weight-reducing food or meal replacement is absorbed because the components are zero energy per se.
Detailed Description
The technical solution of the present invention is illustrated by the following specific examples, but the scope of the present invention is not limited thereto:
example 1
The substances for regulating and controlling the satiety hormone of the organism comprise the following components in percentage by mass: cocoaldehyde 25%, amyl valerate 15%, nerol 20%, hexyl hexanoate 15%, ethyl palmitate 10%, ethyl stearate 15%.
The above composition is dissolved in a ratio of 1g to 99g of absolute ethanol, and then the rat is smelled for 15 min. The abdominal aorta blood of the rats was then drawn and the hormone levels (minus the blank data) were determined using a hormone elisa kit as follows:
| CCK | PYY | GLP-1 | insulin | GIP | Ghrelin |
| 2.283 | 8.883 | 0.772 | -0.814 | 2.745 | -9.110 |
CCK, PYY, GLP-1 and GIP in the table are hormones which can improve the satiety of the body and reduce the appetite, and insulin and ghrelin are hormones which can increase the appetite and increase the hunger.
It can be seen from the hormonal variation data that the rats' blood after sniffing the composition of the present invention had elevated CCK, PYY, GLP-1 and GIP, increased satiety, decreased insulin and ghrelin, and decreased hunger, resulting in decreased hunger and increased satiety as a whole.
Example 2
The substances for regulating and controlling the satiety hormone of the organism comprise the following components in percentage by mass: cocoaldehyde 25%, amyl valerate 15%, nerol 20%, hexyl hexanoate 15%, ethyl palmitate 10%, ethyl stearate 15%.
The above composition 2g was dissolved in 98g of absolute ethanol, and then the rat was smelled for 15 min. The abdominal aorta blood of the rats was then drawn and the hormone levels (minus the blank data) were determined using a hormone elisa kit as follows:
| CCK | PYY | GLP-1 | insulin | GIP | Ghrelin |
| 2.967 | 10.143 | 1.112 | -1.112 | 3.662 | -11.271 |
It can be seen from the hormonal variation data that the rats' blood after sniffing the composition of the present invention had elevated CCK, PYY, GLP-1 and GIP, increased satiety, decreased insulin and ghrelin, and decreased hunger, resulting in decreased hunger and increased satiety as a whole.
Example 3
The substances for regulating and controlling the satiety hormone of the organism comprise the following components in percentage by mass: coconut aldehyde 20%, amyl valerate 18%, nerol 18%, hexyl hexanoate 20%, ethyl palmitate 15%, ethyl stearate 9%.
The above composition is dissolved in a ratio of 1g to 99g of absolute ethanol, and then the rat is smelled for 15 min. The abdominal aorta blood of the rats was then drawn and the hormone levels (minus the blank data) were determined using a hormone elisa kit as follows:
| CCK | PYY | GLP-1 | insulin | GIP | Ghrelin |
| 2.379 | 8.578 | 0.934 | -0.848 | 2.941 | -9.370 |
It can be seen from the hormonal variation data that the rats' blood after sniffing the composition of the present invention had elevated CCK, PYY, GLP-1 and GIP, increased satiety, decreased insulin and ghrelin, and decreased hunger, resulting in decreased hunger and increased satiety as a whole.
Example 4
The substances for regulating and controlling the satiety hormone of the organism comprise the following components in percentage by mass: coconut aldehyde 20%, amyl valerate 18%, nerol 18%, hexyl hexanoate 20%, ethyl palmitate 15%, ethyl stearate 9%.
The above composition 2g was dissolved in 98g of absolute ethanol, and then the rat was smelled for 15 min. The abdominal aorta blood of the rats was then drawn and the hormone levels (minus the blank data) were determined using a hormone elisa kit as follows:
| CCK | PYY | GLP-1 | insulin | GIP | Ghrelin |
| 2.837 | 10.518 | 1.206 | -1.272 | 3.787 | -11.323 |
It can be seen from the hormonal variation data that the rats' blood after sniffing the composition of the present invention had elevated CCK, PYY, GLP-1 and GIP, increased satiety, decreased insulin and ghrelin, and decreased hunger, resulting in decreased hunger and increased satiety as a whole.
Example 5
The substances for regulating and controlling the satiety hormone of the organism comprise the following components in percentage by mass: coconut aldehyde 15%, amyl valerate 15%, nerol 22%, hexyl hexanoate 15%, ethyl palmitate 17%, ethyl stearate 16%.
The above composition 2g was dissolved in 98g of absolute ethanol, and then the rat was smelled for 30 min. The abdominal aorta blood of the rats was then drawn and the hormone levels (minus the blank data) were determined using a hormone elisa kit as follows:
| CCK | PYY | GLP-1 | insulin | GIP | Ghrelin |
| 2.566 | 11.339 | 1.122 | -1.341 | 3.907 | -11.435 |
It can be seen from the hormonal variation data that the rats' blood after sniffing the composition of the present invention had elevated CCK, PYY, GLP-1 and GIP, increased satiety, decreased insulin and ghrelin, and decreased hunger, resulting in decreased hunger and increased satiety as a whole.
Example 6
The substances for regulating and controlling the satiety hormone of the organism comprise the following components in percentage by mass: cocoaldehyde 15%, amyl valerate 30%, nerol 15%, hexyl hexanoate 10%, ethyl palmitate 20%, ethyl stearate 10%.
The above composition is dissolved in a ratio of 1g to 99g of absolute ethanol, and then the rat is smelled for 30 min. The abdominal aorta blood of the rats was then drawn and the hormone levels (minus the blank data) were determined using a hormone elisa kit as follows:
| CCK | PYY | GLP-1 | insulin | GIP | Ghrelin |
| 2.413 | 9.166 | 0.748 | -0.867 | 2.771 | -9.565 |
It can be seen from the hormonal variation data that the rats' blood after sniffing the composition of the present invention had elevated CCK, PYY, GLP-1 and GIP, increased satiety, decreased insulin and ghrelin, and decreased hunger, resulting in decreased hunger and increased satiety as a whole.
Example 7
The substances for regulating and controlling the satiety hormone of the organism comprise the following components in percentage by mass: cocoaldehyde 25%, amyl valerate 15%, nerol 20%, hexyl hexanoate 15%, ethyl palmitate 10%, ethyl stearate 15%.
The above composition was dissolved in a ratio of 1g to 99g of absolute ethanol, and then 10S was smelled into rats. The abdominal aorta blood of the rats was then drawn and the hormone levels (minus the blank data) were determined using a hormone elisa kit as follows:
| CCK | PYY | GLP-1 | insulin | GIP | Ghrelin |
| 0.174 | 0.648 | 0.138 | -0.079 | 0.045 | -0.110 |
It can be seen from the hormonal variation data that the rats' blood after sniffing the composition of the present invention had elevated CCK, PYY, GLP-1 and GIP, increased satiety, decreased insulin and ghrelin, and decreased hunger, resulting in decreased hunger and increased satiety as a whole.
Example 8
The substances for regulating and controlling the satiety hormone of the organism comprise the following components in percentage by mass: coconut aldehyde 20%, amyl valerate 18%, nerol 18%, hexyl hexanoate 20%, ethyl palmitate 15%, ethyl stearate 9%.
The above composition was dissolved in a ratio of 2g to 98g of absolute ethanol, and then 10S was smelled into rats. The abdominal aorta blood of the rats was then drawn and the hormone levels (minus the blank data) were determined using a hormone elisa kit as follows:
| CCK | PYY | GLP-1 | insulin | GIP | Ghrelin |
| 0.198 | 0.813 | 0.167 | -0.088 | 0.063 | -0.166 |
It can be seen from the hormonal variation data that the rats' blood after sniffing the composition of the present invention had elevated CCK, PYY, GLP-1 and GIP, increased satiety, decreased insulin and ghrelin, and decreased hunger, resulting in decreased hunger and increased satiety as a whole.
Sniffing experiment:
eight groups of 2-month-old rats, each with 18 rats, were subjected to sniffing. Five consecutive days, a solution of the substances of examples 1-8 in ethanol was sprayed in a fixed-size space using an atomizer (spraying amount of 3mL/min), and the rats were allowed to move freely and sniff. After smelling, the rats were allowed to eat daily ration and the average food intake for five days was counted, and the food intake of the rats after smelling the components of the different examples is shown in the following table:
therefore, after the substance disclosed by the invention is subjected to an SD rat sniffing test, the daily food intake of rats can be effectively reduced. Therefore, by smelling the substance of the invention, the food intake can be effectively reduced, and the aim of losing weight is achieved.
Claims (10)
1. A substance for regulating and controlling body satiety hormone is characterized by comprising the following components in parts by weight: 6-25 parts of coconut aldehyde, 10-39 parts of amyl valerate, 13-22 parts of nerol, 2-42 parts of hexyl hexanoate, 8-28 parts of ethyl palmitate and 1-18 parts of ethyl stearate.
2. A substance for regulating body satiety hormone according to claim 1, wherein the composition in parts by weight of said components is as follows: 25 parts of coconut aldehyde, 15 parts of amyl valerate, 20 parts of nerol, 15 parts of hexyl hexanoate, 10 parts of ethyl palmitate and 15 parts of ethyl stearate.
3. A substance for regulating body satiety hormone according to claim 1, wherein the composition in parts by weight of said components is as follows: 20 parts of coconut aldehyde, 18 parts of amyl valerate, 18 parts of nerol, 20 parts of hexyl hexanoate, 15 parts of ethyl palmitate and 9 parts of ethyl stearate.
4. A substance for regulating body satiety hormone according to claim 1, wherein the composition in parts by weight of said components is as follows: 15 parts of coconut aldehyde, 15 parts of amyl valerate, 22 parts of nerol, 15 parts of hexyl hexanoate, 17 parts of ethyl palmitate and 16 parts of ethyl stearate.
5. A substance for regulating body satiety hormone according to claim 1, wherein the composition in parts by weight of said components is as follows: 15 parts of coconut aldehyde, 30 parts of amyl valerate, 15 parts of nerol, 10 parts of hexyl hexanoate, 20 parts of ethyl palmitate and 10 parts of ethyl stearate.
6. Use of a substance for regulating body satiety hormone according to any one of claims 1 to 5 for reducing body appetite.
7. Use according to claim 6, wherein the substance or the contents containing the substance is administered to the body by sniffing.
8. Use according to claim 7, wherein the substance is dissolved in ethanol and then smelled, the mass concentration of the components in ethanol being between 0.1 and 12%.
9. Use according to claim 8, wherein the sniffing time is 5S-200 min.
10. Use according to claim 6, wherein the substance is used in dietary supplements, health products, pharmaceuticals and packages for releasing the substance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010720978.0A CN111838659A (en) | 2020-07-24 | 2020-07-24 | Substance for regulating body satiety hormone and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010720978.0A CN111838659A (en) | 2020-07-24 | 2020-07-24 | Substance for regulating body satiety hormone and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111838659A true CN111838659A (en) | 2020-10-30 |
Family
ID=72951189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010720978.0A Pending CN111838659A (en) | 2020-07-24 | 2020-07-24 | Substance for regulating body satiety hormone and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111838659A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060167094A1 (en) * | 2005-01-27 | 2006-07-27 | Donald Fleming | Satiety agent |
| WO2009126132A1 (en) * | 2008-03-31 | 2009-10-15 | Mark Rosenberg | Formulations and methods for modulating satiety |
| WO2016057336A1 (en) * | 2014-10-06 | 2016-04-14 | Jb Scientific, Llc | Systems, apparatus, and methods for delivering a sequence of scents for the purpose of altering an individual's appetite |
-
2020
- 2020-07-24 CN CN202010720978.0A patent/CN111838659A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060167094A1 (en) * | 2005-01-27 | 2006-07-27 | Donald Fleming | Satiety agent |
| WO2009126132A1 (en) * | 2008-03-31 | 2009-10-15 | Mark Rosenberg | Formulations and methods for modulating satiety |
| WO2016057336A1 (en) * | 2014-10-06 | 2016-04-14 | Jb Scientific, Llc | Systems, apparatus, and methods for delivering a sequence of scents for the purpose of altering an individual's appetite |
Non-Patent Citations (5)
| Title |
|---|
| A.R. HIRSCH等: "J Neurol Orthop Med Sufg", 《WEIGHT REDUCTION THROUGH INHALATION OF ODORANTS》 * |
| DR. S.N. MAYE 等: "The Role of Specific Olfactory Stimulation in Appetite Suppression and Weight Loss", 《JOURNAL OF ADVANCEMENT IN MEDICINE》 * |
| 刘扬等: "气味物质经嗅觉通路的减肥作用及机制", 《 中国民族医药学会第二届全国芳香医药学术会议论文集》 * |
| 张艳杰等: "Vana化合物气味减肥效果人群观察", 《包头医学院学报》 * |
| 邹婷婷等: "香气对饱腹感和味觉影响的研究进展", 《食品科学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yamaguchi | Role of nutritional zinc in the prevention of osteoporosis | |
| Anderson | Chromium and insulin resistance | |
| McMellen et al. | Growth factors: possible roles for clinical management of the short bowel syndrome | |
| Wang et al. | Anti-inflammatory activity of di-peptides derived from ovotransferrin by simulated peptide-cut in TNF-α-induced Caco-2 cells | |
| Amos et al. | Zinc and its role in vitamin D function | |
| Buttery | Hormonal control of protein deposition in animals | |
| Sufian et al. | Pork peptone stimulates cholecystokinin secretion from enteroendocrine cells and suppresses appetite in rats | |
| Ahn et al. | Premeal consumption of a protein-enriched, dietary fiber-fortified bar decreases total energy intake in healthy individuals | |
| CN111838659A (en) | Substance for regulating body satiety hormone and application thereof | |
| WO2016000637A1 (en) | Blood-fat reducing composition and application thereof | |
| Cerra | Role of nutrition in the management of malnutrition and immune dysfunction of trauma. | |
| CN111821296A (en) | Substance for regulating and controlling hunger sensation hormone of organism and application thereof | |
| JP2000023635A (en) | Granule nutrient auxiliary food | |
| Garcı́a et al. | Influence of two dietary fibers in the oral bioavailability and other pharmacokinetic parameters of ethinyloestradiol | |
| WO2022237731A1 (en) | Pharmaceutical composition for treating hyperlipidemia and preparation method therefor | |
| KR100809411B1 (en) | Composition For Reducing Body Fat | |
| JP2007230987A (en) | Anti-obestic agent | |
| McCarty | Promotion of interleukin-2 activity as a strategy for ‘rejuvenating’geriatric immune function | |
| Bennett | Effects of the pituitary growth and adrenocorticotropic hormones on the urinary glucose and nitrogen of hypophysectomized diabetic rats | |
| EP4043022A1 (en) | Composition for preventing, ameliorating, or treating metabolic syndromes including obesity, diabetes, hyperlipidemia, and fatty liver | |
| CN109908165A (en) | A kind of composition containing Celastrol and its application | |
| Rudolph | Stack & save | |
| Zhao et al. | Egg Yolk Selenopeptides: Preparation, Characterization, and Immunomodulatory Activity | |
| Agis-Torres et al. | Body growth and substrate partitioning for fat and protein gain in weaned BALB/c mice treated with growth hormone | |
| CN115770290A (en) | Application of plecanatide in preparation of weight-losing and lipid-lowering medicines or medicines with lipase activity inhibition effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201030 |
|
| RJ01 | Rejection of invention patent application after publication |